shutterstock_1155156751_atmosphere1
Atmosphere1 / Shutterstock.com
29 March 2022GenericsAlex Baldwin

MSD, Pfizer try to stop three Steglatro generics

Merck Sharp & Dohme (MSD) and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro (ertugliflozin)—a diabetes treatment that Pfizer licences to MSD.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Generics
5 April 2022   Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.
Big Pharma
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

More on this story

Generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Generics
5 April 2022   Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.
Big Pharma
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

More on this story

Generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Generics
5 April 2022   Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.
Big Pharma
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.